Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database-Reference-Cited by-同舟云学术

Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database

Published:2023-04-17 Issue:9 Volume:22 Page:833-839
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Wang Lin-Yu¹,Liao Liu-Feng¹,Lei Cai-Lu²,Wu Qiong¹,Guo You-Jia¹,Li Yan¹

Affiliation:

1. Department of Pharmacy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China

2. School of Pharmaceutical Science, Guangxi Medical University, Nanning, China

Funder

Guangxi Drug Safety Research Project and Guangxi Medical and Health Appropriate Technology Development, Promotion and Application Project

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2203487

Reference40 articles.

1. Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer

2. Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer

3. Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors

4. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Data mining and analysis of the adverse events derived signals of 4 gadolinium-based contrast agents based on the US Food and drug administration adverse event reporting system;Expert Opinion on Drug Safety;2023-10-14

2. Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system;Expert Opinion on Drug Safety;2023-07-31